PharmAthene fufills BARDA anti-anthrax contract

Pharmaceutical developer PharmAthene said Thursday that it has fulfilled a contract from the Biomedical Advanced Research and Development Authority (BARDA) to develop an anti-anthrax compound.
The contract, finalized in November 2013, stipulated the company be able to provide an indefinite delivery and quantity for its Valortim, an anthrax antitoxin to be stored by the government in a cell bank. This is an effort to boost countermeasure stocks in the case off an outbreak or biological attack of anthrax.
The company specializes in the development and research of compounds to be used as defense mechanisms against biological and chemical threats. Valortim joins SparVax, a candidate antigen vaccine for anthrax, and rBChe bioscavenger, an agent that neutralizes organophosphorus compounds in nerve toxins such as sarin and pesticides. This portfolio of compounds has yet to be approved by the Food and Drug Administration pending clinical trials.
Ever since the anthrax attacks in 2001, the U.S. government has pursued countermeasures to diseases and other agents that could be utilized in biological or chemical warfare. Anthrax in particular is in the same category of highly dangerous and rare diseases that also includes smallpox, Ebola and tularemia.

Organizations in this Story

Biomedical Advanced Researc and Development Authority (BARDA) PharmAthene

Want to get notified whenever we write about any of these organizations ?
Next time we write about any of these organizations, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.